# US 8,772,257 B2 · SDF-1 binding nucleic acids and the use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,772,257 B2
- Document ID: US8772257B2
- Status: Granted
- Kind: B2
- Application number: 12/672,449
- Filed: 2008-08-06
- Published: 2011-09-15
- Granted: 2014-07-08
- Earliest claimed: 2007-08-06
- Assignees: NOXXON Pharma AG
- Applicants: Werner Purschke; Florian Jarosch; Dirk Eulberg; Sven Klussmann; Klaus Buchner; Christian Maasch; Nicole Dinse
- Inventors: Werner Purschke; Florian Jarosch; Dirk Eulberg; Sven Klussmann; Klaus Buchner; Christian Maasch; Nicole Dinse
- Web page: https://patentgrep.com/patent/US8772257B2

## CPC

- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 5/48: of the pancreatic hormones
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/521: {Chemokines}
- C07K 16/24: against cytokines, lymphokines or interferons
- C12N 2310/16: Aptamers
- C12N 2310/351: Conjugate
- C12N 2320/30: Special therapeutic applications
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.

## Claims

### Claim 1

A method for mobilizing a cell that expresses a receptor for SDF-1 comprising exposing said cell to an L-nucleic acid antagonist of SDF-1 or a homolog thereof, each which binds SDF-1, wherein said L-nucleic acid comprises SEQ ID NO:67 and said homolog comprises at least 85% homology to the entire length of SEQ ID NO:67.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said cell is a progenitor cell or a stem cell.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said exposing is in a subject with a disease or a disorder.

### Claim 4 (depends on 3)

The method according to claim 3, wherein said disease is a cancer; a nephropathy; hypertension; a fibrosis; is associated with improper angiogenesis or neovascularization; involves a diseased organ; involves a diseased tissue; an immunodeficiency; or an autoimmune disease.

### Claim 5 (depends on 3)

The method according to claim 3, wherein said disorder is a wound; a burn; a damaged organ, a damaged tissue, associated with a stroke, associated with a heart attack, associated with ischemia, a chemical-induced blood disorder, a bacterial or a viral infection, associated with transplant of an organ or tissue, an inflammatory response or an allergic reaction.

### Claim 6 (depends on 5)

The method according to claim 5, wherein said damaged tissue comprises a vessel, a retina or a choroid.

### Claim 7 (depends on 3)

The method according to claim 3, further comprising chemotherapy and/or radiotherapy.

### Claim 8 (depends on 4)

The method according to claim 4, wherein said autoimmune disease is of the gastrointestinal tract, the skin, the vasculature, the nervous system or the musculo-skeletal system.

### Claim 9 (depends on 4)

The method according to claim 4, wherein said autoimmune disease is selected from the group consisting of Cogan syndrome, autoimmune adrenalitis, Ménière's disease, local inflammations, alopecia greata, primary biliary cirrhosis, Sjörgen's syndrome, scleroderma, CREST syndrome, uveitis, Hashimoto thyroiditis, Grave's disease, hepatitis, glomerulonephritis, anti-phospholipid syndrome, idiopathic pulmonary fibrosis, infertility and peritonitis.

### Claim 10 (depends on 5)

The method according to claim 5, wherein said transplanted organ is liver, kidney, intestine, lung heart, skin or pancreas.

### Claim 11 (depends on 5)

The method according to claim 5, wherein said transplanted tissue is cornea, blood, an islet of Langerhans, a blood vessel or bone marrow.

### Claim 12 (depends on 5)

The method according to claim 5, wherein said allergic reaction comprises a skin or a mucosa.

### Claim 13 (depends on 3)

The method according to claim 3, wherein said exposing mobilizes cells comprising progenitor cells, long-lived plasma cells, B cells, T cells or stem cells into the peripheral circulation of said subject.

### Claim 14 (depends on 3)

The method according to claim 3, further comprising harvesting said cells from said subject.

### Claim 15 (depends on 14)

The method according to claim 14, wherein said harvesting comprises apheresis, leukapheresis, cell sorting and/or flow cytometry.

### Claim 16 (depends on 14)

The method according to claim 14, further comprising growing said harvested cells in vitro.

### Claim 17 (depends on 14, 16)

The method according to claim 14 or 16, further comprising administering said cells to a subject.

### Claim 18 (depends on 13)

The method according to claim 13, wherein said T cells comprise memory T cells.

### Claim 19 (depends on 3)

The method according to claim 3, further comprising administering an agent that inhibits VEGF.

### Claim 20 (depends on 4)

The method according to claim 4, wherein said diseased tissue comprises age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, macular edema or retinal edema.

### Claim 21 (depends on 4, 5)

The method according to claim 4 or 5, wherein said tissue comprises nervous tissue.

### Claim 22 (depends on 4)

The method according to claim 4, wherein said immunodeficiency is WHIM syndrome.